Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB traded up $0.18 during trading hours on Tuesday, hitting $4.94. The company had a trading volume of 338,078 shares, compared to its average volume of 467,358. Y-mAbs Therapeutics, Inc. has a 52-week low of $4.25 and a 52-week high of $17.78. The firm has a fifty day moving average price of $6.22 and a 200-day moving average price of $10.38. The stock has a market capitalization of $223.38 million, a price-to-earnings ratio of -9.15 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the company posted ($0.02) EPS. Research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price for the company. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Finally, Bank of America dropped their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $19.30.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Infinitum Asset Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Y-mAbs Therapeutics by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company’s stock worth $410,000 after buying an additional 7,765 shares in the last quarter. Two Sigma Investments LP raised its position in Y-mAbs Therapeutics by 31.6% in the 4th quarter. Two Sigma Investments LP now owns 88,337 shares of the company’s stock worth $692,000 after buying an additional 21,196 shares during the last quarter. Rafferty Asset Management LLC raised its position in Y-mAbs Therapeutics by 17.6% in the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company’s stock worth $323,000 after buying an additional 6,178 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $99,000. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.